Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active, biopsy, MRI, repeat, surveillance | Leave a comment »
The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, follow-up, MRI/TRUS fusion, risk, surveillance | Leave a comment »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
It will come as no particular surprise that men who have had complications after a prior biopsy tend to be less enthusiastic when it is suggested that they need another one. However, … … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, compliance, complication, repeat | 8 Comments »
Many prostate cancer patients — and particularly those who don’t like the idea of prostate biopsies — think that if one uses MRI-guided biopsies alone one might only need to have one or two biopsy cores taken to accurately diagnose prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, cores, fusion, MRI, MRI/TRUS, number, scan | 7 Comments »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
